Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Chinese Patent Office
Julphar
Queensland Health
Fish and Richardson
Harvard Business School
Healthtrust
AstraZeneca

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018723

« Back to Dashboard

NDA 018723 describes DEPAKOTE, which is a drug marketed by Abbvie and Abbott and is included in four NDAs. It is available from three suppliers. There are six patents protecting this drug and two Paragraph IV challenges. Additional details are available on the DEPAKOTE profile page.

The generic ingredient in DEPAKOTE is divalproex sodium. There are seventeen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
Summary for 018723
Tradename:DEPAKOTE
Applicant:Abbvie
Ingredient:divalproex sodium
Patents:0
Therapeutic Class:Anticonvulsants
Antimigraine Agents
Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 018723
Suppliers and Packaging for NDA: 018723
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723 NDA AbbVie Inc. 0074-6212 N 0074-6212-13
DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723 NDA AbbVie Inc. 0074-6214 N 0074-6214-13

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrengthEQ 250MG VALPROIC ACID
Approval Date:Mar 10, 1983TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrengthEQ 500MG VALPROIC ACID
Approval Date:Mar 10, 1983TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrengthEQ 125MG VALPROIC ACID
Approval Date:Oct 26, 1984TE:ABRLD:Yes

Expired US Patents for NDA 018723

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-001 Mar 10, 1983 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-002 Mar 10, 1983 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-002 Mar 10, 1983 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
Healthtrust
Dow
Queensland Health
QuintilesIMS
Moodys
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.